Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Prostate cancer protein map could guide future treatments

NCT ID NCT07597369

Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protein patterns better, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify which protein targets are most common in different prostate cancer stages, guiding future drug development.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly help patients. Results may not apply to all prostate cancer types or lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

1. Retrospective Cohorts: These four groups are defined by the origin of the archived tumor tissue specimen at Peking University First Hospital (2000-2025). Each cohort includes patients across the spectrum of disease states (castration-sensitive \[CSPC\] and castration-resistant \[CRPC\] prostate cancer) and those with special clinicopathological subtypes (e.g., neuroendocrine differentiation, cribriform/intraductal carcinoma). 2. Prospective Validation Cohort: This group will consist of patients with metastatic prostate cancer recruited at Peking University First Hospital starting January 1, 2026. Participants will provide informed consent for the use of residual tumor tissue (from any anatomic site) obtained during standard clinical care and for prospective clinical follow-up. The core material for analysis is formalin-fixed, paraffin-embedded (FFPE) tumor tissue from all participants, which will be subjected to immunohistochemical (IHC) staining for biomarker evaluation.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For the Retrospective Cohorts (mCRPC, CSPC, Special Pathology): 1. Patients with a pathological diagnosis of prostate cancer. 2. Treated at Peking University First Hospital between January 2000 and 2025. 3. Availability of adequate, qualified formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks for research. 4. Availability of essential clinical and follow-up data in medical records. * For the Prospective Cohort: 1. Age ≥ 18 years. 2. CSPC, primarily includes patients who underwent neoadjuvant therapy and have paired pre- and post-treatment biopsy and surgical specimens; or patients with special clinicopathological subtypes. 3. metastatic prostate cancer patients. 4. Planned or recent (within 6 months prior to enrollment) acquisition of tumor tissue (from metastasis or primary site) as part of standard clinical care, with sufficient residual tissue available for the study. 5. Willing and able to provide written informed consent. Exclusion Criteria: * For All Cohorts: 1. Tumor tissue sample is of insufficient quality or quantity for immunohistochemical (IHC) analysis. 2. Essential clinical or outcome data are missing or irretrievable, which would preclude meaningful analysis. * Specifically for the Prospective Cohort: 1. Any condition that, in the investigator's judgment, would significantly compromise the patient's ability to provide informed consent or comply with the study follow-up procedures. 2. Patient refusal to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Castration-resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma cribriform carcinoma metastatic prostate carcinoma prostate cancer prostate neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic prostate cancer Metastatic prostate cancer (MCRPC) Prostate cancer

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.